BenevolentAI
BenevolentAI uses AI to empower scientists in drug discovery, boasting a versatile platform and a rich pipeline of innovative drug candidates. The company collaborates with leading pharmaceutical firms and maintains a diverse, globally balanced team.
Company Overview
BenevolentAI uses AI to empower scientists to uncover new insights from data, accelerating innovation and increasing the likelihood of discovering successful drugs. The company boasts a versatile and robust AI-enabled drug discovery platform built with expert scientists, leveraging multi-modal data foundations. BenevolentAI specializes in both best-in-class and first-in-class drug candidates, all generated using the Benevolent Platform™.
Collaborations and Partnerships
BenevolentAI partners with leading pharmaceutical and biotech companies to tackle therapeutic challenges and develop novel drugs for complex diseases. Key collaborations include a multi-year partnership with AstraZeneca to develop innovative compounds in oncology, neurology, and immunology. Four targets related to chronic kidney disease and idiopathic pulmonary fibrosis are now part of the AstraZeneca portfolio. Additionally, BenevolentAI has a new strategic collaboration with Merck for Hit Identification to pre-clinical stage development.
Drug Pipeline and Key Assets
BenevolentAI has a rich preclinical and clinical development pipeline. Five high-potential clinical and preclinical assets are currently progressing. The lead asset, BEN-8744, for ulcerative colitis, is in a Phase I clinical study with a topline data readout expected in Q1 2024. Other key assets include BEN-28010, a CHK1 inhibitor for glioblastoma multiforme and metastatic brain tumors, and BEN-34712, an RARɑβ selective agonist for amyotrophic lateral sclerosis (ALS).
Global Presence
BenevolentAI maintains offices in London, Cambridge (UK), and New York. The company boasts a diverse team with over 35 nationalities and a 50/50 gender split globally. This diversity is further supported by the Data Diversity Initiative, aimed at ensuring diverse data representation in AI models.
Sustainability and Strategy
BenevolentAI has a comprehensive sustainability strategy that focuses on enhancing its platform, advancing its drug pipeline, supporting partners, investing in people, and reducing environmental impact. The company's commitment to sustainability reflects its broader dedication to innovation and positive societal impact.